KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eli Lilly (LLY) Buildings (2016 - 2024)

Eli Lilly (LLY) has disclosed Buildings for 13 consecutive years, with $8.8 billion as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Buildings rose 6.36% year-over-year to $8.8 billion, compared with a TTM value of $8.8 billion through Dec 2024, up 6.36%, and an annual FY2024 reading of $8.8 billion, up 6.36% over the prior year.
  • Buildings was $8.8 billion for Q4 2024 at Eli Lilly, up from $8.3 billion in the prior quarter.
  • Across five years, Buildings topped out at $8.8 billion in Q4 2024 and bottomed at $7.3 billion in Q4 2020.
  • Average Buildings over 5 years is $8.0 billion, with a median of $7.9 billion recorded in 2022.
  • The sharpest move saw Buildings rose 3.58% in 2021, then rose 6.36% in 2024.
  • Year by year, Buildings stood at $7.3 billion in 2020, then increased by 3.58% to $7.6 billion in 2021, then increased by 4.32% to $7.9 billion in 2022, then rose by 4.6% to $8.3 billion in 2023, then grew by 6.36% to $8.8 billion in 2024.
  • Business Quant data shows Buildings for LLY at $8.8 billion in Q4 2024, $8.3 billion in Q4 2023, and $7.9 billion in Q4 2022.